Language: BG BG
← Back to results
Recruiting NCT05106387

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Conditions: Chronic Kidney Disease (CKD)

Sponsor: Regeneron Pharmaceuticals

trial.available_in: БГ
Overview
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Who can participate
Inclusion Criteria: 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\]. 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide informed consent signed by study patient or legally acceptable representative Exclusion Criteria: 1.There are no exclusion criteria for this study. Note: Other protocol defined Inclusion/Exclusion criteria may apply
Interventions
Noninterventional
DRUG
Locations 9
United States (9)
John Hopkins Hospital
Baltimore , Maryland
Comprehensive Transplant Center
Chicago , Illinois
Cedars-Sinai Medical Center
Los Angeles , California
University of Minnesota
Minneapolis , Minnesota
Yale University of Medicine
New Haven , Connecticut
New York University Langone Health
New York , New York
University of California Irvine
Orange , California
Penn Transplant Institute
Philadelphia , Pennsylvania
Connie Frank Transplant Center at UCSF
San Francisco , California
Technical details
Status
Recruiting
Study type
OBSERVATIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
70 Years
Healthy volunteers
No
Start date
19.10.2023
Completion date
23.02.2028
Registry ID
NCT05106387
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.